Chiron Submits NDA For Inhaled Immunosuppressant Pulminiq For Lung Transplant
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has requested priority review for the aerosolized cyclosporine product for chronic lung transplant rejection. The Oct. 14 NDA is limited to chronic rejection because pivotal study failed to show significance for acute rejection.